Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome

  • Sachin Punatar
  • Alok Gupta
  • Jayant Gawande
  • Bhausaheb Bagal
  • Libin Mathew
  • Sadhana Kannan
  • Navin KhattryEmail author
Original Article


Chronic graft versus host disease (cGVHD) is a common late complication of allogenic hematopoietic stem cell transplant (HSCT). We analyzed risk factors, pattern and long term transplant outcomes of cGVHD at a tertiary cancer centre. Seventy-seven consecutive patients who underwent HSCT for acute leukemia were included. Forty (52 %) patients developed cGVHD; 24 (60 %) extensive stage while 16 (40 %) limited stage. Oral cavity was the commonest site of involvement (25 patients) followed by liver, skin and lung. We found that female donor to male recipient transplant and diagnosis of acute lymphoblastic leukemia (ALL) were the only factors associated with increased risk of cGVHD. The incidence of leukemia relapse was 18 % in patients who developed cGVHD compared to 51 % in those who did not (P = 0.002). Four year overall survival and relapse free survival (RFS) were 62 and 46 % in patients who developed cGVHD compared to 29 % (P < 0.001) and 29 % (P < 0.001) in patients who did not develop cGVHD, respectively. We conclude that cGVHD is more common in male patients with female donors and in patients transplanted for ALL. Oral cavity is the commonest site of cGVHD in our patients and transplant related survival outcomes are superior in patients who develop cGVHD.


Acute leukemia Chronic graft-versus-host disease Allogeneic stem cell transplantation Outcome Risk factors 


Conflict of interest

The authors declare no conflict of interest.


  1. 1.
    Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2008) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transpl 28:121–129CrossRefGoogle Scholar
  2. 2.
    Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al (2002) Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 100:1192–1200CrossRefPubMedGoogle Scholar
  3. 3.
    Lee SJ, Vogelsang G, Flowers ME (2003) Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl 9:215–233CrossRefGoogle Scholar
  4. 4.
    Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459–2464PubMedGoogle Scholar
  5. 5.
    Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al (2003) Graft-versus-host disease following allogenic transplantation from HLA-identical sibling with anti thymocyte globulin-based reduced-intensity preparative regimen. Blood 102:470–476CrossRefPubMedGoogle Scholar
  6. 6.
    Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M (2013) Incidence and pattern of graft-versus-host disease in patients undergoing allogenic transplantation after non myeloablative conditioning with total lymphoid irradiation and anti thymocyte globulin. Bone Marrow Res. doi: 10.1155/2013/414959 PubMedCentralPubMedGoogle Scholar
  7. 7.
    Gota V, Pathak K, Mittal S et al (2014) A limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil for prophylaxis of acute graft versus host disease in allogeneic stem cell transplantation. Bone Marrow Transpl 49:S295Google Scholar
  8. 8.
    Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217CrossRefPubMedGoogle Scholar
  9. 9.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11:945–956CrossRefGoogle Scholar
  10. 10.
    Higman MA, Vogelsang GB (2004) Chronic graft versus host disease. Br J Haematol 125:435–454CrossRefPubMedGoogle Scholar
  11. 11.
    Dhédin N, Prébet T, De Latour RP, Katsahian S, Kuentz M, Piard N et al (2012) Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transpl 47:1564–1568CrossRefGoogle Scholar
  12. 12.
    Konopacki J, Porcher R, Robin M, Bieri S, Cayuela JM, Larghero J et al (2012) Long-term follow up after allogenic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin. Haematologica 97:710–716PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Solano C, Martinez C, Brunet S, Tomás JF, Urbano-Ispizua A, Zuazu J et al (1998) Chronic graft versus host disease after allogenic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case–control study. Bone Marrow Transpl 22:1129–1135CrossRefGoogle Scholar
  14. 14.
    Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al (2002) Severity of chronic graft-versus-host disease: association with treatment related mortality and relapse. Blood 100:406414Google Scholar
  15. 15.
    Pidala J (2011) Graft-vs-host disease following allogenic hematopoietic cell transplantation. Cancer Control 18:268–276PubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2015

Authors and Affiliations

  • Sachin Punatar
    • 1
  • Alok Gupta
    • 1
  • Jayant Gawande
    • 1
  • Bhausaheb Bagal
    • 1
  • Libin Mathew
    • 1
  • Sadhana Kannan
    • 2
  • Navin Khattry
    • 1
    Email author
  1. 1.Bone Marrow Transplant Unit, Department of Medical OncologyACTREC, Tata Memorial CentreMumbaiIndia
  2. 2.Department of BiostatisticsACTREC, Tata Memorial CentreMumbaiIndia

Personalised recommendations